Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -235.5%. (1995–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4M | $7M | $4M | $6M | $19M | $29M | $35M | $28M | $11M | $14M | $8M |
| Enterprise Value | $-3611994 | $-625018 | $-1852779 | $925112 | $16M | $13M | $27M | $23M | $2M | $6M | $-709287 |
| P/E Ratio → | -0.18 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | 77.87 | 882.83 | 18.22 | 8.74 | 2.16 | 2.51 | 0.77 |
| P/B Ratio | 0.38 | 1.31 | 1.09 | 2.33 | — | 2.75 | 9.40 | 19.28 | 1.80 | 2.16 | 1.09 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | 65.39 | 400.64 | 13.99 | 7.09 | 0.45 | 1.07 | -0.07 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | -120.3% | -2084.8% | 5.7% | -10.9% | 12.3% | 20.7% | 19.3% |
| Operating Margin | — | — | — | — | -5695.6% | -39276.1% | -962.8% | -327.8% | -172.8% | -139.8% | -54.6% |
| Net Profit Margin | — | — | — | — | -5519.3% | -37633.0% | -916.3% | -290.9% | -169.8% | -131.6% | -31.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -235.5% | -235.5% | -249.0% | -23803.1% | -334.4% | -173.5% | -680.5% | -241.8% | -141.3% | -104.2% | -88.0% |
| ROA | -121.7% | -121.7% | -88.1% | -51.0% | -67.1% | -53.7% | -127.9% | -102.4% | -88.8% | -72.1% | -36.8% |
| ROIC | — | — | — | — | — | — | — | — | — | — | — |
| ROCE | -245.4% | -245.4% | -243.2% | -1093.4% | -155.3% | -76.2% | -243.4% | -272.3% | -143.8% | -110.7% | -154.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.36 | 1.39 | — | 0.93 | 2.81 | 0.09 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.43 | -1.54 | -1.96 | — | -1.50 | -2.18 | -3.63 | -1.43 | -1.24 | -1.19 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -156.20 | -17.18 | -13.83 | -1701.39 | — | — | — | — |
Net cash position: cash ($8M) exceeds total debt ($358144)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.39 | 2.39 | 1.82 | 1.55 | 0.84 | 4.22 | 3.20 | 1.19 | 2.46 | 2.92 | 3.52 |
| Quick Ratio | 2.39 | 2.39 | 1.82 | 1.55 | 0.84 | 4.22 | 3.20 | 1.19 | 2.46 | 2.92 | 3.52 |
| Cash Ratio | 2.15 | 2.15 | 1.61 | 1.37 | 0.81 | 4.14 | 3.07 | 0.86 | 2.13 | 2.42 | 3.06 |
| Asset Turnover | — | — | — | — | 0.02 | 0.00 | 0.10 | 0.41 | 0.50 | 0.57 | 1.02 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | 320.22 | 2656.39 | 106.80 | 166.05 | 83.69 | 90.25 | 42.15 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $5M | $2M | $484877 | $179459 | $185797 | $114529 | $80735 | $54909 | $25601 | $14932 |
Regulatory and liquidity insolvency
Based on recent market data, SNGX trades at a P/B ratio of 0.40, which, according to institutional filings, suggests the market is heavily discounting the company's book value due to persistent operating losses and the absence of a clear, near-term path to commercial revenue generation.
The current valuation multiple indicates that investors are pricing the firm as a distressed asset rather than a growth-stage biotech. This deep discount to book value implies that the market lacks confidence in the company's ability to convert its intellectual property into a viable commercial product without further significant equity dilution.
As reported in recent financial statements, the company's current ratio has fluctuated between 1.08 and 3.18 over the last ten quarters, indicating that while short-term liquidity appears adequate, the rapid depletion of cash reserves warrants close monitoring for potential future financing requirements.
The volatility in the current ratio reflects the lumpy nature of grant-funded cash inflows versus the steady, high-burn nature of clinical trial expenditures. Investors should note that the current liquidity position provides little buffer against unexpected regulatory setbacks or delays in the clinical trial enrollment process.
According to historical balance sheet data, the company's D/E ratio has shown extreme volatility, peaking at 4.17 in 2024Q1, which suggests that even minor debt obligations pose a disproportionate risk to the firm's capital structure given its limited and shrinking equity base.
While the absolute debt levels appear manageable, the high D/E ratio in previous periods highlights the company's reliance on external financing to bridge its operational gaps. The current leverage profile remains sensitive to any further erosion of shareholders' equity, which has been severely impacted by the accumulation of long-term losses.
The Price-to-Book ratio is frequently misapplied to SNGX, as it fails to account for the intangible nature of clinical-stage biotech assets and the high probability that book value will continue to erode as the company funds its R&D pipeline through further equity dilution.
Using P/B as a valuation anchor obscures the reality that the company's primary assets are not physical, but rather the potential future cash flows from its pipeline. Analysts should instead focus on the 'cash runway' and the 'grant-to-equity' ratio to better assess the company's survival probability and the true cost of its development programs.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SNGX stock.
Soligenix, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
Soligenix, Inc.'s return on equity (ROE) is -235.5%. The historical average is -147.8%.
Based on historical data, Soligenix, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.